Trinity Biotech Announces Acquisition Of Metabolomics Diagnostics, Co Has Developed An Innovative Test, PrePsia, To Accurately Predict The Risk Of Preeclampsia In Pregnant Women
Portfolio Pulse from Benzinga Newsdesk
Trinity Biotech has acquired Metabolomics Diagnostics, gaining access to the PrePsia test, which predicts preeclampsia risk in pregnant women. The test will be commercialized in the U.S. by 2025, enhancing Trinity's diagnostic capabilities.
September 24, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trinity Biotech's acquisition of Metabolomics Diagnostics introduces the PrePsia test, enhancing its diagnostic offerings. This strategic move is expected to drive growth, particularly in the U.S. market.
The acquisition of Metabolomics Diagnostics provides Trinity Biotech with a new diagnostic test, PrePsia, which is expected to be a significant growth driver. The test's early prediction capability for preeclampsia and planned U.S. commercialization by 2025 are likely to positively impact Trinity's market position and revenue potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100